Despite some officials and anti-vaccine activist groups trying to scare the public, a study conducted by the Center for Disease Control has concluded that the Pfizer and Moderna vaccines are potent in real-world circumstances.
Researchers tested vaccinated and non-vaccinated health care personnel, first responders, and other frontline healthcare employees. Almost 4,000 in eight locations received COVID tests every week from Dec. 14 to March 13.
The tests revealed only three infections of the nearly 2,500 of those who were fully immunized. The results state that eight infections of almost 500 people who only had one dose.
Of the 944 unvaccinated, 161 people were infected. From the manuscript:
“Prospective cohorts of health care personnel, first responders, and other essential and frontline workers over 13 weeks in eight U.S. locations confirmed that authorized mRNA COVID-19 vaccines (Pfizer-BioNTech’s BNT162b2 and Moderna’s mRNA-1273) are highly effective in real-world conditions,” the CDC concluded. “Vaccine effectiveness of full immunization with two doses of mRNA vaccines was 90% (95% CI = 68%–97%) against RT-PCR–confirmed SARS-CoV-2 infection.”
The parties involved essentially help patients with the infection in which they are constantly exposed. If they have these results, the outcome of the non-frontline workers could be even more promising. Again, from the study:
“These findings are consistent with those from the mRNA vaccines’ Phase III trials (1,2) and recent observational studies of the mRNA vaccine effectiveness against severe COVID-19 (3). The findings complement and expand upon these preceding reports by demonstrating that the vaccines can also reduce the risk for infection regardless of COVID-19–associated illness symptom status (4,5). Reducing the risk for transmissible infection, which can occur among persons with asymptomatic infection or among persons several days before symptoms onset (6), is especially important among health care personnel, first responders, and other essential and frontline workers given their potential to transmit the virus through frequent close contact with patients and the public.
Partial immunization (≥14 days after first dose but before second dose) provided preventive benefits with vaccine effectiveness of 80%. This finding is similar to an analysis of Phase III trial results (1,2,7) and two other recent estimates of vaccine effectiveness for partial immunization with Pfizer-BioNTech vaccine among health care personnel, including a vaccine effectiveness (≥21 days after first dose) of 72% (95% CI = 58%–86%) against PCR-confirmed infection identified by routine testing in the United Kingdom (4) and a vaccine effectiveness (>14 days after first dose) of 60% (95% CI = 38%–74%) against PCR-confirmed infection identified by records review in Israel (5). This finding is also consistent with early descriptive findings of SARS-CoV-2 employee and clinical testing results by mRNA vaccination status in the United States (8,9).”